Health Care

Consumers and advocates urged state insurance regulators on Friday to deny a 12.5 percent rate increase proposed by Anthem Blue Cross and Blue Shield, Connecticut's largest health insurer.

American International Group Inc. swung to loss in the third quarter, falling short of Wall Street expectations as the giant insurer faces calls from shareholders Carl Icahn and John Paulson to break up.

Embattled Jefferies and Co. investment banker Sage Kelly has resigned amid a messy scandal.

Catalyst for Change: When former JPMorgan banker Ilan Ganot’s son was diagnosed with a rare form of muscular dystrophy, this father didn’t miss a beat to dedicate his life to saving his son’s.

The U.S. drug maker's shares advanced only modestly as Roche denied having a need to raise cash. 

Incyte Corp said it would discontinue some of the trials testing its already approved blood cancer drug, Jakafi, after the treatment's effectiveness was found to be insufficient.

AstraZeneca warned that revenue and earnings would drop this year due to the arrival of cheap generic rivals to its cholesterol fighter Crestor.

Theranos Inc.'s main retail partner is suspending some ties to the blood-testing laboratory in the wake of a critical regulatory inspection report.

Bristol-Myers Squibb forecast 2016 earnings slightly above Wall Street estimates.

Pfizer Inc and Allergan Plc are considering combining, the Wall Street Journal said on Wednesday.

Amgen Inc. raised its 2015 guidance as the biotechnology company reported that its third-quarter earnings rose 50% on stronger revenue led by Enbrel and other key drugs.

Gilead Sciences Inc said on Tuesday its quarterly net profit rose 32 percent, driven by sales of hepatitis C drugs that beat Wall Street estimates.

Celgene Corp. has reached a deal to buy fellow biopharmaceutical company Receptos Inc. for about $7.2 billion, enhancing its portfolio of immune-inflammatory disease treatments with the addition of Ozanimod.

A massive earthquake in Nepal has exposed the woeful state of its medical facilities as hospitals struggle to treat vast numbers of injured with limited supplies and staff.

Patent expirations on big-name drugs such as Lipitor and Plavix has resulted in modestly less spending on medicines in the United States for the first time in at least 55 years, according to a report released on Thursday.

30 cancer patients are currently using wearable technology to ease cancer treatments.

The Zika virus is becoming more commonplace in the U.S. and experts say the South will feel the impact the most.

Valeant Pharmaceuticals is planning to appoint a new chief executive while its CEO remains under hospital care, said people familiar with the matter.

William Ackman's Pershing Square Capital Management LP trimmed its stake in Valeant Pharmaceuticals International Inc. to 8.5%, a move the hedge fund said was related to year-end tax planning.

KaloBios Pharmaceuticals Inc said on Wednesday that it had been notified by Nasdaq that its stock would be delisted using the exchange operator's "discretionary" authority.